| Name | XMD8-92 |
| Description | XMD8-92 is an effective and specific BMK1/ERK5 inhibitor (Kd: 80 nM). |
| Kinase Assay | KiNativ profiling of XMD8-92 is carried out with both an ATP and ADP acylphosphate-desthiobiotin with the following modifications. HeLa cell lysates (5 mg/mL total protein) are incubated in the presence of XMD8-92 at 50 μM, 10 μM, 2 μM, 0.8 μM, and 0 μM for 15 minutes prior to addition of the ATP or ADP acylphosphate probe (5 μM final probe concentration). All reactions are performed in duplicate. Probe reactions proceeded for 10 minutes and the reaction stopped by the addition of urea and processed for MS analysis. Samples are analyzed by LC-MS/MS on a linear ion trap mass spectrometer using a time segmented "target list" designed to collect MS/MS spectra from all kinase peptide-probe conjugates that can be detected in HeLa cell lysates. This target list is generated and validated by prior exhaustive analysis of HeLa lysates. Up to four characteristic fragment ions for each kinase peptide-probe conjugate are used to extract signals for each kinase, and a comparison of inhibitor treated to control (untreated) lysates allow for precise determination of % inhibition at each point. A manuscript describing the details of this targeted mass spectrometry approach is in preparation[1]. |
| In vitro | XMD8-92 significantly inhibits the growth of pancreatic tumor xenografts by downregulating DCLK1 and several of its downstream targets. At a dose of 50 mg/kg, administered intraperitoneally (i.p.), XMD8-92 blocks tumor cell proliferation and tumor-associated angiogenesis, resulting in significant suppression of tumor growth in both xenografted human and syngeneic mouse models. |
| In vivo | Hydroxysafflor yellow A (HSYA) inhibits the activation of hepatic stellate cells, while XMD8-92 can significantly block this inhibition and prevent the HSYA-mediated downregulation of MEF2C. By inhibiting the activation of BMK1, XMD8-92 significantly induces the expression of p21 in cells and inhibits the proliferation of cancer cells. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 19 mg/mL (40.04 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.21 mM), Sonication is recommended.
|
| Keywords | XMD8-92 | XMD-8-92 | XMD892 | XMD8 92 | protein | promyelocytic | leukemia | Inhibitor | inhibit | HMEC | Extracellular signal regulated kinases | ERK | EpigeneticReaderDomain | Epigenetic Reader Domain | cancer | BMI-1 | BMI1 | bFGF |
| Inhibitors Related | Rosiglitazone | Urea | Gum arabic | Daidzein | Lactose | Curcumin | Magnesium acetate tetrahydrate | Gluconate Calcium | Naphthol AS-E | 2,3-Butanediol | (-)-Limonene | Cloxiquine |
| Related Compound Libraries | Highly Selective Inhibitor Library | Pain-Related Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Autophagy Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | MAPK Inhibitor Library |
United States
